Trinity Biotech Management
Management criteria checks 2/4
Trinity Biotech's CEO is John Gillard, appointed in Nov 2020, has a tenure of 5.58 years. total yearly compensation is $1.14M, comprised of 57.9% salary and 42.1% bonuses, including company stock and options. directly owns 0.049% of the company’s shares, worth $6.67K. The average tenure of the management team and the board of directors is 8.2 years and 3.7 years respectively.
Key information
John Gillard
Chief executive officer
US$1.1m
Total compensation
| CEO salary percentage | 57.95% |
| CEO tenure | 5.6yrs |
| CEO ownership | 0.05% |
| Management average tenure | 8.2yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | US$1m | US$660k | -US$37m |
| Sep 30 2025 | n/a | n/a | -US$36m |
| Jun 30 2025 | n/a | n/a | -US$36m |
| Mar 31 2025 | n/a | n/a | -US$37m |
| Dec 31 2024 | US$975k | US$676k | -US$31m |
| Sep 30 2024 | n/a | n/a | -US$20m |
| Jun 30 2024 | n/a | n/a | -US$22m |
| Mar 31 2024 | n/a | n/a | -US$34m |
| Dec 31 2023 | US$710k | US$473k | -US$37m |
| Sep 30 2023 | n/a | n/a | -US$39m |
| Jun 30 2023 | n/a | n/a | -US$46m |
| Mar 31 2023 | n/a | n/a | -US$34m |
| Dec 31 2022 | US$863k | US$452k | -US$44m |
| Sep 30 2022 | n/a | n/a | -US$32m |
| Jun 30 2022 | n/a | n/a | -US$22m |
| Mar 31 2022 | n/a | n/a | -US$13m |
| Dec 31 2021 | US$593k | US$346k | -US$2m |
| Sep 30 2021 | n/a | n/a | -US$8m |
| Jun 30 2021 | n/a | n/a | -US$2m |
| Mar 31 2021 | n/a | n/a | -US$2m |
| Dec 31 2020 | US$312k | US$52k | -US$6m |
Compensation vs Market: John's total compensation ($USD1.14M) is above average for companies of similar size in the US market ($USD641.77K).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
CEO
John Gillard (44 yo)
Mr. John Gillard is President & CEO of Trinity Biotech plc since December 17, 2023 and served as Chief Financial Officer since November 17, 2020 until December 17, 2023. He serves as Executive Director at...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.6yrs | US$1.14m | 0.049% $ 6.7k | |
| Founder | 34yrs | US$60.00k | 2.4% $ 324.5k | |
| Executive Director of Business Development & Executive Director | no data | US$48.00k | 0.34% $ 46.5k | |
| Interim Chief Financial Officer | no data | no data | no data | |
| Director of Operations | no data | no data | no data | |
| Chief Technology Officer | no data | no data | no data | |
| Chief Information Officer | 10.8yrs | no data | no data | |
| Head of North America Commercial Operations | less than a year | no data | no data |
Experienced Management: TRIB's management team is seasoned and experienced (8.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.6yrs | US$1.14m | 0.049% $ 6.7k | |
| Founder | 3.7yrs | US$60.00k | 2.4% $ 324.5k | |
| Executive Director of Business Development & Executive Director | 19.4yrs | US$48.00k | 0.34% $ 46.5k | |
| Non-Executive Director | less than a year | US$15.00k | no data | |
| Independent Director | 2.8yrs | US$51.00k | 0% $ 0 |
Experienced Board: TRIB's board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/08 10:11 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Trinity Biotech plc is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura McGuigan | B. Riley Securities, Inc. |
| Lawrence Solow | CJS Securities, Inc. |
| William Bonello | Craig-Hallum Capital Group LLC |